John P. Iwanicki is quoted in BioWorld Today on dispute between Amgen Inc. and F. Hoffman – La Roche Ltd.

January 23, 2007

The article discusses Amgen Inc.’s patent estate that allowed them access to F. Hoffman – La Roche’s cell lines for their European product, Mircera.  Iwanicki comments that Amgen’s motivation for seeking the cell lines is to simply find out how the drug operates in the human body.  If allowed into the U.S., Mircera would be a competitor for Amgen’s product, Aranesp.


Please click here to view the article.

Posted: January 23, 2007

Contact Banner Witcoff Share on LinkedIn View this page as a pdf Share on Twitter Email this page Print this page